Survodutide
Tested in peopleGet notified when the evidence changes.
It has been tested in people, but it is not an approved medicine. The studies are usually small.
Compiled and reviewed by the PeptideSearch Editorial Team · Status checked 2026-08-04
Also called BI 456906
Hits two hormone targets for weight loss and liver disease. In human trials, not approved.
Official status: Not nominated for 503A compounding · Checked 2026-08-04
Can a doctor prescribe this?
- Small pharmacy (503A)
- Never put forward to FDA
- Large outsourcing facility (503B)
- Never put forward to FDA
Investigational. Not approved and not legal to compound.
503A is a pharmacy making a single prescription for one patient. 503B is a facility making batches. They are governed by separate lists. Where a category is shown, it is a position on the FDA's list of substances that have been put forward and are still being worked through — not the final list, which is set by rulemaking. Category 1 means the FDA does not plan to act against a pharmacy that makes it while the review runs.
Lab suppliers we list: 5
Doses used in research
Taken word for word from the studies and trials listed on this page. This is not a recommendation and not a dose for anyone to take.
- Study in peopleSurvodutide Once Weekly in Adults with Obesity and Type 2 Diabetes.
The New England journal of medicine · 2026
- Study in peopleSurvodutide for the Treatment of Obesity Disease in Japanese Participants: Rationale, Design and Baseline Characteristics of the Phase 3 SYNCHRONIZE-JP Trial.
Diabetes, obesity & metabolism · 2026
- Study in peopleWeight reduction-dependent/-independent effects of survodutide on liver endpoints: Mediation analysis of a phase 2 trial in MASH.
Hepatology (Baltimore, Md.) · 2026
- Study in peopleSurvodutide Once Weekly for the Treatment of Adults with Obesity.
The New England journal of medicine · 2026
- Study in peopleDual Glucagon and GLP-1 Receptor Agonist Survodutide Improves Biomarkers of Beta-Cell Function and Insulin Sensitivity in People With Type 2 Diabetes or Living With Overweight/Obesity.
Diabetes, obesity & metabolism · 2026
- Study in peopleBaseline characteristics in the SYNCHRONIZE™-2 randomized phase 3 trial of survodutide, a glucagon receptor/GLP-1 receptor dual agonist, for obesity in people with type 2 diabetes.
Diabetes, obesity & metabolism · 2026
- Study in peopleSurvodutide for Obesity in Chinese Adults: Phase 3 Randomized Trial Design and Baseline Characteristics (SYNCHRONIZE™-CN).
Diabetes therapy : research, treatment and education of diabetes and related disorders · 2026
- Study in peopleSurvodutide for the treatment of obesity: Mechanistic rationale, clinical evidence, and remaining uncertainties.
Contemporary clinical trials · 2026
- Study in peopleSurvodutide for treatment of obesity: Baseline characteristics of participants in a randomized, double-blind, placebo-controlled, phase 3 trial (SYNCHRONIZE™-1).
Diabetes, obesity & metabolism · 2026
- Study in peopleSurvodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial.
Nature medicine · 2026
- Study in peopleAuthor Correction: Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial.
Nature medicine · 2026
- Study in peopleSurvodutide for treatment of obesity: rationale and design of two randomized phase 3 clinical trials (SYNCHRONIZE™-1 and -2).
Obesity (Silver Spring, Md.) · 2025
- Study in peopleSurvodutide, a glucagon receptor/glucagon-like peptide-1 receptor dual agonist, improves blood pressure in adults with obesity: A post hoc analysis from a randomized, placebo-controlled, dose-finding, phase 2 trial.
Diabetes, obesity & metabolism · 2025
- Study in peopleSubgroup analysis by sex and baseline BMI in people with a BMI ≥27 kg/m<sup>2</sup> in the phase 2 trial of survodutide, a glucagon/GLP-1 receptor dual agonist.
Diabetes, obesity & metabolism · 2025
- Study in peopleGlucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial.
The lancet. Diabetes & endocrinology · 2024
- Study in peopleEfficacy, tolerability and pharmacokinetics of survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, in cirrhosis.
Journal of hepatology · 2024
- Study in peopleDose-response effects on HbA<sub>1c</sub> and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial.
Diabetologia · 2024
- Study in peopleSurvodutide for the Treatment of Obesity: Rationale and Design of the SYNCHRONIZE Cardiovascular Outcomes Trial.
JACC. Heart failure · 2024
- Study in peopleA Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis.
The New England journal of medicine · 2024
- Study in peopleA randomized Phase I study of the safety, tolerability, pharmacokinetics and pharmacodynamics of BI 456906, a dual glucagon receptor/glucagon-like peptide-1 receptor agonist, in healthy Japanese men with overweight/obesity.
Diabetes, obesity & metabolism · 2023
- Study in peoplePhase I studies of the safety, tolerability, pharmacokinetics and pharmacodynamics of the dual glucagon receptor/glucagon-like peptide-1 receptor agonist BI 456906.
Diabetes, obesity & metabolism · 2023
- Data from people, not a trialGastrointestinal adverse effects of GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists: A narrative expert review of approved therapies, oral formulations, and pipeline agents.
Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition · 2026
- Data from people, not a trialFrom Potency Ratios to Target Engagement: Translational Identifiability of Multi-Incretin Receptor Balance
2026
- Animal study, rats or miceHepatic GCGR is required for the superior weight loss and metabolic effects of a structurally related analogue of the dual GCGR/GLP-1R agonist survodutide in mice.
Diabetes, obesity & metabolism · 2026
- Animal study, rats or miceSurvodutide acts through circumventricular organs in the brain and activates neuronal regions associated with appetite regulation.
Molecular metabolism · 2026
- Animal study, rats or miceNephroprotective Effects of the Dual GCGR/GLP-1R Agonist Survodutide in Hypertension-Accelerated Diabetic Kidney Disease.
Diabetes, obesity & metabolism · 2026
- Animal study, rats or miceNovel NPY2R agonist BI 1820237 provides synergistic anti-obesity efficacy when combined with the GCGR/GLP-1R dual agonist survodutide.
Molecular metabolism · 2025
- Animal study, rats or miceThe dual GCGR/GLP-1R agonist survodutide: Biomarkers and pharmacological profiling for clinical candidate selection.
Diabetes, obesity & metabolism · 2024
- Lab test method, not a health studyDevelopment and validation of a multiplexed LC-HRMS method for nine GLP-1 receptor agonists and its pharmaceutical application.
Journal of chromatography. A · 2026
- Hypothesis, not a tested studyPhenotype-Directed Precision Therapeutics: A Framework for Multi-Agonist Therapy in Obesity, MASH and Cardio-Renal-Metabolic Disorders
2026
- No abstract available, not yet classifiedDual incretin agonist survodutide benefits in MASLD
2026
- No abstract available, not yet classifiedInterpreting Survodutide Renoprotection in a Hyperfiltration Model.
Diabetes, obesity & metabolism · 2026
- Charcoal-Based Depletion Method to Improve Drug Tolerance in Neutralizing Antibody Assays for Therapeutic Peptides.
The AAPS journal · 2026
- Pharmacological management of obesity: Current landscape and emerging therapies.
Indian journal of pharmacology · 2026
- No abstract available, not yet classifiedOperationalising disease modification in obesity trials: A blueprint based on the SYNCHRONIZE-1 survodutide study.
Diabetes, obesity & metabolism · 2026
- No abstract available, not yet classifiedDoes Survodutide Provide Renoprotection Beyond Its Metabolic and Haemodynamic Effects in Diabetic Kidney Disease?
Diabetes, obesity & metabolism · 2026
- Survodutide: A Dual GLP-1/Glucagon Agonist Reshaping Cardiometabolic Care.
Cardiology in review · 2025
- Review of earlier workHow does survodutide work? Plain language review of a potential new medication for obesity and liver disease.
Therapeutic advances in gastroenterology · 2026
- Review of earlier workThe Power of Two: Harnessing Dual Glucagon and Incretin Signaling for Treatment of Obesity and Metabolic Dysfunction-Associated Steatohepatitis-A Narrative Review with a Translational Focus.
Obesity reviews : an official journal of the International Association for the Study of Obesity · 2026
- Review of earlier work[New Therapeutic Approaches for MASH: Mechanisms and Clinical Promise].
Zeitschrift fur Gastroenterologie · 2026
- Review of earlier workObesity pharmacotherapy reimagined: The era of multi-receptor agonists and next-generation metabolic modulators, perspectives and controversies.
Metabolism open · 2026
- Review of earlier workMASLD: Established Knowledge and Emerging Directions - Guideline Updates.
Zeitschrift fur Gastroenterologie · 2026
- Review of earlier workFrom pathophysiology to therapy: dual and triple agonists as a new frontier in metabolic dysfunction-associated steatotic liver disease.
Frontiers in pharmacology · 2026
- Review of earlier workPathogenesis-Informed Phenotype-Guided Therapy for MASH: A Three-Axis Translational Framework Within the MASLD Spectrum.
Biomedicines · 2026
- Review of earlier workComparative Efficacy and Safety of Glucagon Receptor Agonists on Metabolic Outcomes: A Network Meta-Analysis of Randomised Controlled Trials.
Endocrinology, diabetes & metabolism · 2026
- Review of earlier workEfficacy and Safety of Dual GLP-1/Glucagon Receptor Agonism in Overweight and Obesity: A Class-Specific Systematic Review and Meta-Analysis.
Diabetes, obesity & metabolism · 2026
- Review of earlier workA review of survodutide: a new dual acting agonist.
Minerva endocrinology · 2026
- Review of earlier workEfficacy and Safety of Dual and Triple Glucagon-Like Peptide-1-Based Polyagonists in Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis: A Systematic Review and Meta-Analysis.
Cureus · 2026
- Review of earlier workCardiovascular Effects of Glucagon Receptor Signaling Alone and Combined With Glucagon-Like Peptide-1 Receptor Signaling in Multiagonists: A Narrative Review With a Translational Focus.
Journal of the American Heart Association · 2026
- Review of earlier workFrom Oxyntomodulin to Retatrutide: Engineering Metabolic Polyagonism
2026
- Review of earlier workRecent Studies on the Effectiveness and Safety of Anti-Obesity Medications: A Scoping Review.
Diabetes, metabolic syndrome and obesity : targets and therapy · 2026
- Review of earlier workAnti-Obesity Medications in Longevity and Aesthetic Medicine.
Journal of clinical medicine · 2026
- Review of earlier workEfficacy of pharmacotherapies in improving liver fibrosis among patients with MASLD and fibrosis stages of F1-F3: systematic review and network meta-analysis.
Journal of translational medicine · 2026
- Review of earlier workTherapeutic horizons in metabolic dysfunction-associated steatohepatitis.
The Journal of clinical investigation · 2025
- Review of earlier workEfficacy and safety of survodutide on glycemic control and weight loss in adults: A systematic review and meta-analysis.
Diabetes, obesity & metabolism · 2025
- Review of earlier workEffect of survodutide, a glucagon and GLP-1 receptor dual agonist, on weight loss: a meta-analysis of randomized controlled trials.
Diabetology & metabolic syndrome · 2024
Spot an error? corrections@peptidesearch.org